Literature DB >> 25795476

Spectral-domain optical coherence tomography angiography of choroidal neovascularization.

Talisa E de Carlo1, Marco A Bonini Filho2, Adam T Chin3, Mehreen Adhi1, Daniela Ferrara3, Caroline R Baumal3, Andre J Witkin3, Elias Reichel3, Jay S Duker3, Nadia K Waheed4.   

Abstract

PURPOSE: To describe the characteristics as well as the sensitivity and specificity of detection of choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA) using spectral-domain optical coherence tomography.
DESIGN: Observational, retrospective study. PARTICIPANTS: Seventy-two eyes of 61 subjects (48 eyes of 43 subjects with CNV, 24 eyes of 18 subjects without CNV).
METHODS: Patients imaged using the prototype AngioVue OCTA system (Optovue, Inc, Fremont, CA) between August 2014 and October 2014 at New England Eye Center were assessed. Patients in whom CNV was identified on OCTA were evaluated to define characteristics of CNV on OCTA: size using greatest linear dimension (small, <1 mm; medium, 1-2 mm; large, >2 mm), appearance (well-circumscribed, poorly circumscribed), and presence of subretinal and intraretinal fluid. Concurrently, an overlapping second cohort of patients who underwent same-day OCTA and fluorescein angiography (FA) for suspected CNV was evaluated to estimate sensitivity and specificity of OCTA in detecting CNV using FA as ground truth. MAIN OUTCOME MEASURES: Choroidal neovascularization appearance, CNV size, and presence of subretinal and intraretinal fluid.
RESULTS: In 48 eyes, CNV was visualized on OCTA. Thirty-one eyes had CNV associated with neovascular age-related macular degeneration. Size of CNV was small in 23% (7/31), medium in 42% (13/31), and large in 35% (11/31). Poorly circumscribed vessels, subretinal fluid, and intraretinal fluid each were seen in 71% (22/31). Seven eyes had CNV associated with central serous chorioretinopathy. Size of CNV was small in 71% (5/7) and large in 29% (2/7). Seventy-one percent (5/7) had well-circumscribed vessels, 86% (6/7) had subretinal fluid, and 14% (1/7) had intraretinal fluid. Thirty eyes with OCTA and same-day FA were evaluated to determine sensitivity and specificity of CNV detection on OCTA. Sensitivity was 50% (4/8) and specificity was 91% (20/22).
CONCLUSIONS: Using OCTA allows the clinician to visualize CNV noninvasively and may provide a method for identifying and guiding treatment of CNV. The specificity of CNV detection on OCTA compared with FA seems to be high. Future studies with larger sample sizes are needed to elaborate better on the sensitivity and specificity of CNV detection and to illustrate clinical usefulness.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25795476     DOI: 10.1016/j.ophtha.2015.01.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  103 in total

1.  Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy.

Authors:  Ian A Thompson; Alia K Durrani; Shriji Patel
Journal:  Eye (Lond)       Date:  2018-12-03       Impact factor: 3.775

2.  Automated choroidal neovascularization detection algorithm for optical coherence tomography angiography.

Authors:  Li Liu; Simon S Gao; Steven T Bailey; David Huang; Dengwang Li; Yali Jia
Journal:  Biomed Opt Express       Date:  2015-08-25       Impact factor: 3.732

Review 3.  [Clinical applications of OCT angiography].

Authors:  P P Fang; M Lindner; J S Steinberg; P L Müller; M Gliem; P Charbel Issa; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2016-01       Impact factor: 1.059

4.  The Association Between Macula and ONH Optical Coherence Tomography Angiography (OCT-A) Vessel Densities in Glaucoma, Glaucoma Suspect, and Healthy Eyes.

Authors:  Patricia I C Manalastas; Linda M Zangwill; Fabio B Daga; Mark A Christopher; Luke J Saunders; Takuhei Shoji; Tadamichi Akagi; Rafaella C Penteado; Adeleh Yarmohammadi; Min H Suh; Felipe A Medeiros; Robert N Weinreb
Journal:  J Glaucoma       Date:  2018-03       Impact factor: 2.503

5.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

6.  Linear and planar reflection artifacts on swept-source and spectral-domain optical coherence tomography due to hyperreflective crystalline deposits.

Authors:  Serena Fragiotta; Pedro Fernández-Avellaneda; Mark P Breazzano; Lawrence A Yannuzzi; Christine A Curcio; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-26       Impact factor: 3.117

7.  Select Features of Diabetic Retinopathy on Swept-Source Optical Coherence Tomographic Angiography Compared With Fluorescein Angiography and Normal Eyes.

Authors:  David A Salz; Talisa E de Carlo; Mehreen Adhi; Eric Moult; WhooJhon Choi; Caroline R Baumal; Andre J Witkin; Jay S Duker; James G Fujimoto; Nadia K Waheed
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

8.  [Fluorescein, indocyanine green and optical coherence tomography angiography in patients with native exudative age-related macular degeneration].

Authors:  L J B Pauleikhoff; K Blobner; K Wehrmann; N Feucht; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2018-07       Impact factor: 1.059

9.  Analysis of Scleral Feeder Vessel in Myopic Choroidal Neovascularization Using Optical Coherence Tomography Angiography.

Authors:  Ricardo Noguera Louzada; Daniela Ferrara; Eduardo Amorim Novais; Eric Moult; Emily Cole; Mark Lane; James Fujimoto; Jay S Duker; Caroline R Baumal
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-10-01       Impact factor: 1.300

10.  Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy.

Authors:  Ju Young Kim; Oh Woong Kwon; Hyun Sub Oh; Soon Hyun Kim; Yong Sung You
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-30       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.